Price still isn’t right for Biogen’s blockbuster drug

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
3rd March, 2019
Michel Vounatsos, CEO, Biogen n Vounatsos was paid $13.6 million in pay, shares and other compensation in 2017

Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.

It is being reimbursed by numerous health systems across Europe - but to varying degrees.

The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Full vaccination more effective than a booster campaign, Nphet advisor says

Majority of HSE special budget for reducing waiting lists to go unused this year

Health Daniel Murray 6 days ago

Health group headed by Irishman fires 1,400 staff over vaccine refusal

Health Róisín Burke 6 days ago

Flyefit to create 120 jobs as part of €10m expansion

Health Eva Short 1 week ago